A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On April 1st, 2025, TuHURA Biosciences, Inc.

Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and ...

Researchers studied trends in survival following FDA approval of immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma.

CTLA4 Inhibitors Market forecast to 2035 covers market size, key trends, competitive landscape, and growth opportunities in cancer immunotherapy and autoimmune diseases.

Find out how Bristol Myers Squibb was honored for 50 years of service in Lawrence, from local support to global medical breakthroughs.

KAIST researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master ...

Iovance stock drops 90% despite historic approval for Amtagvi. Click here for a full investment analysis of IOVA stock.

The FDA recently ... With this approval, how does the durvalumab data apply to community oncology settings? This is a paradigm, one that is familiar to oncologists that practice in community-based ...

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with microsatellite instable tumors.

Despite the absence of any approved VISTA inhibitors to date, a growing body of research underscores the potential of targeting this immune checkpoint as a novel approach to overcome tumor immune ...